<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fecal microbiota capsules (oral): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fecal microbiota capsules (oral): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fecal microbiota capsules (oral): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="141502" href="/d/html/141502.html" rel="external">see "Fecal microbiota capsules (oral): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58272940"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vowst</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58231948"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Microbiota</li></ul></div>
<div class="block doa drugH1Div" id="F58275328"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> On the day prior to the first dose, administer a bowel prep according to the manufacturer's directions.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5aea94f0-cdab-48d8-a2fa-64de68a2cca2">
<i>Clostridioides difficile</i> infection, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Clostridioides difficile</i> infection, prophylaxis: Oral: </b>4 capsules once daily for 3 consecutive days, beginning 2 to 4 days after completion of <i>C. difficile</i> treatment regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35045228','lexi-content-ref-36780159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35045228','lexi-content-ref-36780159'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F58275330"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, not expected to be systemically absorbed.</p></div>
<div class="block doha drugH1Div" id="F58275331"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, not expected to be systemically absorbed.</p></div>
<div class="block doe drugH1Div" id="F58275329"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F58234601"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (31%), constipation (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Gastrointestinal: Diarrhea (3% to 10%), flatulence (4%), nausea (3%)</p></div>
<div class="block coi drugH1Div" id="F58231951"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F58275324"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Food allergies: Because product is manufactured from human fecal matter, may contain food allergens; however, potential for the product to cause adverse reactions due to food allergens is unknown.</p>
<p style="text-indent:-2em;margin-left:4em;">• Transmissible infectious agents: Manufactured from human fecal matter; may carry risk of transmitting infectious agents. Infections thought to be transmitted by this product should be reported to the manufacturer.</p></div>
<div class="block foc drugH1Div" id="F58272941"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vowst: Fecal microbiota spores, live-brpk</p></div>
<div class="block geq drugH1Div" id="F58272939"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block adm drugH1Div" id="F58275333"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Swallow capsules whole; do not open, crush, dissolve, or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">First dose: Administer a bowel prep according to manufacturer's directions and do not eat or drink, except small amounts of water, for ≥8 hours prior to first dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Subsequent doses: Administer on an empty stomach before the first meal of the day.</p></div>
<div class="block use drugH1Div" id="F58231950"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Clostridioides difficile</i> infection, prophylaxis:</b> Prevention of recurrence of <i>C. difficile</i> infection (CDI) in patients ≥18 years of age following antibiotic treatment of recurrent CDI.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Not indicated for treatment of CDI.</p></div>
<div class="block mst drugH1Div" id="F58275321"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Fecal microbiota (live) (oral) may be confused with fecal microbiota (live) (rectal).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F58246340"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58246337"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antibiotics: Fecal Microbiota (Live) (Oral) may diminish the therapeutic effect of Antibiotics. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F58275322"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal developmental toxicity studies have not been conducted.</p></div>
<div class="block brc drugH1Div" id="F58275323"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if fecal microbiota (live) would be present in breast milk following oral administration.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F58275332"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Do not eat or drink, except small amounts of water, for ≥8 hours prior to first dose. Administer subsequent doses on an empty stomach before the first meal of the day.</p></div>
<div class="block pha drugH1Div" id="F58275327"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Live purified Firmacutes spores modulate bile acid concentrations and restore short chain fatty acids resulting in colonization resistance to <i>C. difficile</i> and restoration of intestinal eubiosis (Martinez-Gili 2020; Soveral 2022).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-35045228">
<a name="35045228"></a>Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent <i>Clostridioides difficile</i> infection. <i>N Engl J Med</i>. 2022;386(3):220-229. doi:10.1056/NEJMoa2106516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fecal-microbiota-capsules-oral-drug-information/abstract-text/35045228/pubmed" id="35045228" target="_blank">35045228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32893721">
<a name="32893721"></a>Martinez-Gili L, McDonald JAK, Liu Z, et al. Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent <i>Clostridioides difficile</i> infection and beyond: the contribution of gut microbial-derived metabolites. <i>Gut Microbes</i>. 2020;12(1):1810531. doi:10.1080/19490976.2020.1810531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fecal-microbiota-capsules-oral-drug-information/abstract-text/32893721/pubmed" id="32893721" target="_blank">32893721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36780159">
<a name="36780159"></a>Sims MD, Khanna S, Feuerstadt P, et al; ECOSPOR IV Investigators. Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single-arm trial. <i>JAMA Netw Open</i>. 2023;6(2):e2255758. doi:10.1001/jamanetworkopen.2022.55758<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fecal-microbiota-capsules-oral-drug-information/abstract-text/36780159/pubmed" id="36780159" target="_blank">36780159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36156924">
<a name="36156924"></a>Soveral LF, Korczaguin GG, Schmidt PS, Nunes IS, Fernandes C, Zárate-Bladés CR. Immunological mechanisms of fecal microbiota transplantation in recurrent <i>Clostridioides difficile</i> infection. <i>World J Gastroenterol</i>. 2022;28(33):4762-4772. doi:10.3748/wjg.v28.i33.4762<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fecal-microbiota-capsules-oral-drug-information/abstract-text/36156924/pubmed" id="36156924" target="_blank">36156924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vowst.1">
<a name="Vowst.1"></a>Vowst (fecal microbiota) [prescribing information]. Brisbane, CA: Aimmune Therapeutics, Inc; April 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 141486 Version 142.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
